| Title | Alterations in Acrolein Metabolism Contribute to Alzheimer's Disease. |
| Publication Type | Journal Article |
| Year of Publication | 2018 |
| Authors | Tsou, H-H, Hsu, W-C, Fuh, J-L, Chen, S-P, Liu, T-Y, Wang, H-T |
| Journal | J Alzheimers Dis |
| Volume | 61 |
| Issue | 2 |
| Pagination | 571-580 |
| Date Published | 2018 |
| ISSN | 1875-8908 |
| Keywords | Acetylcysteine, Acrolein, Aged, Aged, 80 and over, Alzheimer Disease, Biomarkers, Case-Control Studies, Creatinine, Disease Progression, Early Diagnosis, Female, Humans, Male, Middle Aged |
| Abstract | Alzheimer's disease (AD) is a detrimental neurodegenerative disease, and early diagnosis appears to be the key to successful treatment. Acrolein, a byproduct of lipid peroxidation, has been shown to contribute to the pathological process of AD. This study recruited 118 elderly subjects consisting of 58 non-demented control subjects and 62 AD patients. We analyzed the acrolein-related metabolites in the plasma, cerebrospinal fluid (CSF), and urine of all subjects. We found that the levels of acrolein-conjugated protein (Acr-PC) in the plasma (p = 0.00012) and CSF (p = 0.00161) of AD patients were significantly higher than those of control subjects, whereas the levels of a urinary acrolein metabolite, 3-hydroxypropyl mercapturic acid (3-HPMA), were markedly decreased (p = 0.00882) in AD patients. These data suggest that deregulated acrolein metabolism may be correlated with neuronal damage in AD patients, which might provide further insights into the disease progression and early diagnosis of AD. |
| DOI | 10.3233/JAD-170736 |
| Alternate Journal | J. Alzheimers Dis. |
| PubMed ID | 29226874 |
